ClinicalTrials.gg
CompletedNCT04977388Updated Apr 13, 2026Results posted

NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome

A Phase 1/2 interventional study of Droxidopa and Placebo in Menkes Disease and Occipital Horn Syndrome, sponsored by Stephen G. Kaler, MD. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Stephen G. Kaler, MD · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Autonomic Nervous System Diseases with a site in United States — 12 open to participants now, 16 under way, none of them phase 3. Autonomic Nervous System Diseases · United States.

Enrollment
29th of 31
3 · median 20
Started
2021
with 2 others
Phase 1/2
4 of 49
1 open now
Registered
31st of 49
by date

Among the 49 studies in Autonomic Nervous System Diseases with a site in United States, this one is the 29th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2021, is one of 4 in phase 1/2, and was the 31st registered.

Autonomic Nervous System Diseases

108 studies on the registry are indexed under Autonomic Nervous System Diseases; 29 are open to participants now.

Browse Autonomic Nervous System Diseases studies →

Open to participants now

12 of the 49 studies in Autonomic Nervous System Diseases with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Autonomic Nervous System Diseases studies recruiting now, 6 (29%) set no upper age limit and 12 (57%) stop at 75 or younger; 6 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Autonomic Nervous System Diseases with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate whether Northera (Droxidopa) is safe and effective in young adults with Menkes disease who survived the most severe complications of their illness or adults with occipital horn syndrome (OHS), who have trouble with intermittent low blood pressure and other symptoms of dysautonomia. The outcomes and information from this study may help adult survivors of Menkes disease and individuals with OHS lead more normal day-to-day lives.

Read the detailed description

This pilot clinical trial will evaluate the safety, tolerability, dosing, and preliminary efficacy of Northera (Droxidopa) treatment in young adults who survived the major neurodegenerative and neurocognitive effects of Menkes disease through early Copper Histidinate treatment. We hypothesize that Northera (Droxidopa) in Menkes disease survivors with symptoms of dysautonomia (e.g., syncope, dizziness, orthostatic hypotension, abnormal sinoatrial conduction, nocturnal bradycardia, and bowel or bladder dysfunction) from persistent deficiency of the copper-dependent enzyme, dopamine-β-hydroxylase, will be safe, and correct or improve blood neurochemical levels, raise systolic blood pressure, and produce symptomatic improvement and better overall quality of life. We will test this hypothesis in six to ten Menkes disease survivors or OHS patients in a double-blind placebo-controlled randomized crossover clinical trial.

03

Conditions studied

  • Menkes Disease
  • Occipital Horn Syndrome

Keywords

  • Dysautonomia
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult persons with Menkes disease who survived beyond the expected natural history, attained independent ambulation, attend (or attended) school, and reached adulthood after early CuHis treatment for three years or adults with Occipital Horn Syndrome, who manifest clinical signs and symptoms of dysautonomia, e.g., orthostatic hypotension: specifically, a decrease in systolic or diastolic blood pressure of at least 20 or 10 mm Hg, respectively, within three minutes after standing, and/or chronic diarrhea: production of loose stools with or without increased stool frequency for more than four weeks immediately preceding enrollment.
  2. History of at least thrice weekly occurrence of dizziness/feeling lightheaded while standing upright and/or thrice weekly episodes of diarrhea or an urgent need to defecate after food ingestion for more than four weeks immediately preceding enrollment.
  3. Documented mutation in ATP7A.
  4. Must sign and date an Form (ICF).
  5. Age ≥ 18 years of age.
  6. Ability to adhere to the prescribed oral Northera (Droxidopa) regimen.
  7. Willingness to comply with all study visits and procedures.

Exclusion criteria

Exclusion Criteria:

  1. Pre-existing liver (e.g., hepatitis, biliary atresia, cirrhosis) or kidney disease (i.e., calculated \<30 ml/min).
  2. History of hypertension, anti-hypertensive therapy, heart failure (or decreased ), cardiac arrhythmia, or bleeding diatheses.
  3. Any disease or condition that, in the opinion of the Investigator, has a high probability of precluding the subject from completing the study or where the subject cannot or will not appropriately comply with study requirements.
  4. Any alpha-1 adrenoreceptor agonist, beta-blocker, DOPA decarboxylase inhibitor, midodrine, ephedrine, or any triptan medication as a concomitant medication.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
3 participants (actual)

Study arms

  • Active comparator
    Northera™ (Droxidopa) (Treatment A)

    Northera (Droxidopa) (Treatment A) will be provided to adult subjects as a capsule with 100mg, 200mg, or 300mg of Northera (Droxidopa) contained within gelatin color capsules (sky blue and white, size 0) based on findings from the dose titration visit. These capsules are physically indistinguishable from the Treatment B (placebo) capsules. Frequency of administration (by mouth) will be twice daily for six weeks.

    Drug: Droxidopa

  • Placebo comparator
    Placebo (Treatment B)

    Empty gelatin color capsules (sky blue and white, size 0) filled with cellulose microcrystalline and physically indistinguishable from Treatment A capsules. Frequency of administration (by mouth) will be twice daily for six weeks

    Other: Placebo

Interventions

  • Subjects will self-administer capsules of Droxidopa by mouth twice daily for six weeks.

    Also known as: Northera

  • OtherPlacebo

    Subjects will self-administer capsules of placebo by mouth twice daily for six weeks.

06

What researchers measure

Primary outcomes

  1. Treatment Related Adverse Events as Assessed by CTCAE v4.0

    Treatment related adverse events as assessed by CTCAE v 4.0 by study arm

    Time frame: TEAEs in 6 week periods of either active drug (droxidopa) or placebo

Secondary outcomes

  1. Mean Change in Systolic Blood Pressure in Tilt Position

    Change in systolic BP in tilt position during each treatment arm (droxidopa and placebo) compared to baseline.

    Time frame: Change in systolic BP in tilt position during each 6 week treatment arm (droxidopa and placebo) compared to baseline.

  2. Mean Change in Diastolic Blood Pressure in Tilt Position

    The change in diastolic BP in tilt position during each treatment arm (droxidopa and placebo) compared to baseline.

    Time frame: The change in diastolic BP in tilt position during each 6 week treatment arm (droxidopa and placebo) compared to baseline.

  3. Plasma Catechol Levels

    Change in plasma catechols between placebo and droxidopa treatment arms

    Time frame: Change in plasma catechols between each 6 week treatment arm (droxidopa and placebo)

  4. Change From Baseline in Daily Bowel Movements

    Change from baseline in daily bowel movements

    Time frame: Change from baseline in daily bowel movements per day during each 6 week treatment arm (droxidopa and placebo).

  5. Change From Baseline in Time Standing Duration

    Change from baseline in Time standing duration

    Time frame: Change from baseline in standing time duration during each 6 week treatment arm (droxidopa and placebo).

  6. Change From Baseline in Timed Up and Go (TUG) Test Performance

    Change from baseline in Timed Up and Go (TUG) test performance

    Time frame: Change from baseline in TUG test performance during each 6 week treatment arm (droxidopa and placebo)

  7. Change From Baseline in 6 Minute Walk Test Performance

    Change from baseline in 6 minute walk test performance

    Time frame: Change from baseline in the 6MW distance during each 6 week treatment arm (droxidopa and placebo)

  8. Change From Baseline in Scores on the Orthostatic Hypotension Symptom Assessment (OHSA) Questionnaire

    Change from baseline in scores on the Orthostatic Hypotension Symptom Assessment questionnaire. The scale rates the severity of OH symptoms from 0 to 10 ; with 10 defined as the worst possible.

    Time frame: Change from baseline in OHSA score during each 6 week treatment arm (droxidopa and placebo)

07

Results

Posted Apr 13, 2026
Limitations and caveats
No specific study limitations and caveats.

Participant flow

Three adult participants were consented and screened for eligibility between July 2021 and October 2023.

First Intervention (6 weeks)
Participant flow — First Intervention (6 weeks)
MilestoneArm 1 (Northera™ (Droxidopa) First Then Placebo)Arm 2- Placebo First Then Northera (Droxidopa)
Started12
Completed12
Not completed00
Washout (7-10 days)
Participant flow — Washout (7-10 days)
MilestoneArm 1 (Northera™ (Droxidopa) First Then Placebo)Arm 2- Placebo First Then Northera (Droxidopa)
Started0102
Completed0102
Not completed00
Second Intervention (6 weeks)
Participant flow — Second Intervention (6 weeks)
MilestoneArm 1 (Northera™ (Droxidopa) First Then Placebo)Arm 2- Placebo First Then Northera (Droxidopa)
Started0102
Completed0102
Not completed00

Outcome measures

SecondaryMean Change in Systolic Blood Pressure in Tilt Position

Change in systolic BP in tilt position during each treatment arm (droxidopa and placebo) compared to baseline.

Time frame:
Change in systolic BP in tilt position during each 6 week treatment arm (droxidopa and placebo) compared to baseline.
Reported as:
Mean · mm/Hg
Mean Change in Systolic Blood Pressure in Tilt Position
mm/HgNorthera (Droxidopa)Placebo
Mean Change in Systolic Blood Pressure in Tilt Position-25 ± 12.5-22 ± 6.5
SecondaryMean Change in Diastolic Blood Pressure in Tilt Position

The change in diastolic BP in tilt position during each treatment arm (droxidopa and placebo) compared to baseline.

Time frame:
The change in diastolic BP in tilt position during each 6 week treatment arm (droxidopa and placebo) compared to baseline.
Reported as:
Mean · mmHg
Mean Change in Diastolic Blood Pressure in Tilt Position
mmHgNorthera (Droxidopa)Placebo
Mean Change in Diastolic Blood Pressure in Tilt Position-8.6 ± 7.5-15 ± 4.5
SecondaryPlasma Catechol Levels

Change in plasma catechols between placebo and droxidopa treatment arms

Time frame:
Change in plasma catechols between each 6 week treatment arm (droxidopa and placebo)
Reported as:
Mean · pg/ml
Plasma Catechol Levels
pg/mlNorthera (Droxidopa)Placebo
Plasma Catechol Levels65 ± 820 ± 4
SecondaryChange From Baseline in Daily Bowel Movements

Change from baseline in daily bowel movements

Time frame:
Change from baseline in daily bowel movements per day during each 6 week treatment arm (droxidopa and placebo).
Reported as:
Mean · bowel movements per day
Change From Baseline in Daily Bowel Movements
bowel movements per dayNorthera™ (Droxidopa)Placebo
Change From Baseline in Daily Bowel Movements7 ± 78 ± 8
SecondaryChange From Baseline in Time Standing Duration

Change from baseline in Time standing duration

Time frame:
Change from baseline in standing time duration during each 6 week treatment arm (droxidopa and placebo).
Reported as:
Mean · Seconds
Change From Baseline in Time Standing Duration
SecondsNorthera (Droxidopa)Placebo
Change From Baseline in Time Standing Duration300 ± 50175 ± 25
SecondaryChange From Baseline in Timed Up and Go (TUG) Test Performance

Change from baseline in Timed Up and Go (TUG) test performance

Time frame:
Change from baseline in TUG test performance during each 6 week treatment arm (droxidopa and placebo)
Reported as:
Mean · seconds
Change From Baseline in Timed Up and Go (TUG) Test Performance
secondsNorthera (Droxidopa)Placebo
Change From Baseline in Timed Up and Go (TUG) Test Performance10 ± 29 ± 1
SecondaryChange From Baseline in 6 Minute Walk Test Performance

Change from baseline in 6 minute walk test performance

Time frame:
Change from baseline in the 6MW distance during each 6 week treatment arm (droxidopa and placebo)
Reported as:
Mean · meters
Change From Baseline in 6 Minute Walk Test Performance
metersNorthera (Droxidopa)Placebo
Change From Baseline in 6 Minute Walk Test Performance250 ± 75200 ± 75
PrimaryTreatment Related Adverse Events as Assessed by CTCAE v4.0

Treatment related adverse events as assessed by CTCAE v 4.0 by study arm

Time frame:
TEAEs in 6 week periods of either active drug (droxidopa) or placebo
Reported as:
Number · adverse events
Treatment Related Adverse Events as Assessed by CTCAE v4.0
adverse eventsNorthera (Droxidopa)Placebo
Treatment Related Adverse Events as Assessed by CTCAE v4.0106
SecondaryChange From Baseline in Scores on the Orthostatic Hypotension Symptom Assessment (OHSA) Questionnaire

Change from baseline in scores on the Orthostatic Hypotension Symptom Assessment questionnaire. The scale rates the severity of OH symptoms from 0 to 10 ; with 10 defined as the worst possible.

Time frame:
Change from baseline in OHSA score during each 6 week treatment arm (droxidopa and placebo)
Reported as:
Mean · Scores on a scale
Change From Baseline in Scores on the Orthostatic Hypotension Symptom Assessment (OHSA) Questionnaire
Scores on a scaleNorthera (Droxidopa)Placebo
Change From Baseline in Scores on the Orthostatic Hypotension Symptom Assessment (OHSA) Questionnaire-0.67 (-1.55 to 0.22)0 (0 to 0)

Adverse events

Collected over From enrollment up to 20 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open Label: Northera (Droxidopa)0/3 (0%)0/3 (0%)1/3 (33.3%)
Crossover: Northera (Droxidopa)0/3 (0%)0/3 (0%)3/3 (100%)
Crossover: Placebo0/3 (0%)0/3 (0%)1/3 (33.3%)
Most frequent other events
Most frequent other events
EventOpen Label: Northera (Droxidopa)Crossover: Northera (Droxidopa)Crossover: Placebo
VomitingGastrointestinal disorders1/32/31/3
HeadacheNervous system disorders0/32/31/3
Elevated blood pressureCardiac disorders1/32/30/3
potential Urinary Tract infectionRenal and urinary disorders0/31/30/3
Pre-syncopal episode while on baseline tilt table testNervous system disorders0/30/31/3
Minimally elevated creatinine levelRenal and urinary disorders0/30/31/3
Moderate Occult blood noted on urinalysisRenal and urinary disorders0/30/31/3
SeizureNervous system disorders0/30/31/3
ProteinuriaRenal and urinary disorders0/30/31/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Northera (Droxidopa) First Then PlaceboPlacebo First Then Northera (Droxidopa)Total
<=18 years000
Between 18 and 65 years123
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Northera (Droxidopa) First Then PlaceboPlacebo First Then Northera (Droxidopa)Total
Female000
Male123
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Northera (Droxidopa) First Then PlaceboPlacebo First Then Northera (Droxidopa)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White112
More than one race000
Unknown or Not Reported000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Northera (Droxidopa) First Then PlaceboPlacebo First Then Northera (Droxidopa)Total
Hispanic or Latino000
Not Hispanic or Latino112
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(Participants)Northera (Droxidopa) First Then PlaceboPlacebo First Then Northera (Droxidopa)Total
United States123
Height
Height(cm)Northera (Droxidopa) First Then PlaceboPlacebo First Then Northera (Droxidopa)Total
Mean166.2 (166.2 to 166.2)174.85 (173 to 176.7)171.97 (166.2 to 176.7)
Weight
Weight(kg)Northera (Droxidopa) First Then PlaceboPlacebo First Then Northera (Droxidopa)Total
Mean68.0 (68.0 to 68.0)52.6 (46.2 to 59)57.73 (46.2 to 68)
08

Study locations

1 site
  • Vagelos College of Physicians and Surgeons, Columbia University
    New York, New York 10032, United States
09

References and documents

Publications

  • Kaler MM, Brock G, Jeanty CJ, Iammarino MA, Hampton KA, Pham MT, Sabo BT, Lowes LP, Sullivan P, Goldstein DS, Kaler SG. Safety and efficacy of droxidopa for dysautonomia in adults with Menkes disease and occipital horn syndrome in the USA: a randomised phase 1/2a crossover trial. EClinicalMedicine. 2026 Apr 13;94:103898. doi: 10.1016/j.eclinm.2026.103898. eCollection 2026 Apr. PubMed 42016919 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Oct 2023, 27 months.

Results were first posted in Apr 2026, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2021
First posted
Jul 26, 2021
StartActual
Jul 12, 2021
Primary completionActual
Oct 30, 2023
CompletionActual
Jun 29, 2024
Results first posted
Apr 13, 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04977388
Lead sponsor
Stephen G. Kaler, MD
Responsible party
Stephen G. Kaler, MD (Professor, Nationwide Children's Hospital) — Sponsor-investigator
First posted
Jul 26, 2021
Start date
Jul 12, 2021
Primary completion
Oct 30, 2023
Completion
Jun 29, 2024
Results posted
Apr 13, 2026
Last update
Apr 13, 2026

Study contacts

Stephen G Kaler, MD
principal investigator · Vagelos College of Physicians & Surgeons, Columbia University, New York, NY

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Droxidopa

Start the discussion